Contract award notice
Results of the procurement procedure
Section I: Contracting
authority
I.1) Name and addresses
Commercial Medicines Unit
2nd Floor, Rutland House
Runcorn
WA7 2ES
UK
E-mail: michelle.clarke6@nhs.net
NUTS: UK
Internet address(es)
Main address: https://cmu.bravosolution.co.uk
I.4) Type of the contracting authority
Ministry or any other national or federal authority, including their regional or local subdivisions
I.5) Main activity
Other: public procurement
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
NHS Framework Agreement for Branded Pharmaceuticals — North of England Tranche A.
Reference number: CM/PHR/15/5484
II.1.2) Main CPV code
33600000
II.1.3) Type of contract
Supplies
II.1.4) Short description
For NHS Framework Agreement for Branded Pharmaceuticals for the North of England Tranche A.
Offer reference number: CM/PHR/15/5484
Period of framework agreement: 1.3.2017 to 28.2.2019 plus an option to extend for up to 24 months.
II.1.6) Information about lots
This contract is divided into lots:
Yes
II.1.7) Total value of the procurement
Value excluding VAT:
200 311 092.00
GBP
II.2) Description
Lot No: 1
II.2.1) Title
North of England comprising North West, North East and Yorkshire
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKD
UKE
UKC
II.2.4) Description of the procurement
Products associated with the lots are listed on Document No 06c of the Invitation to Offer. Each individual National Product Code (NPC) pack description in each of the regions (North of England, North West, North East and Yorkshire) is deemed to be a separate product for the application on the award criteria. There is no restriction on the number of products that bidders can offer for, or be awarded. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England, The framework may also be used by private sector contractors and agents working on behalf of the above.
II.2.5) Award criteria
Quality criterion: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document
/ Weighting: See over
Cost criterion: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document
/ Weighting: See over
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 2
II.2.1) Title
North East England
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKC
II.2.4) Description of the procurement
Products associated with the lots are listed on Document No 06c of the Invitation to Offer. Each individual National Product Code (NPC) pack description in each of the regions (North of England, North West, North East and Yorkshire) is deemed to be a separate product for the application on the award criteria. There is no restriction on the number of products that bidders can offer for, or be awarded. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England. The framework may also be used by private sector contractors and agents working on behalf of the above.
II.2.5) Award criteria
Quality criterion: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document
/ Weighting: See over
Cost criterion: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document
/ Weighting: See over
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 3
II.2.1) Title
North West England
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKD
II.2.4) Description of the procurement
Products associated with the lots are listed on Document No 06c of the Invitation to Offer. Each individual National Product Code (NPC) pack description in each of the regions (North of England, North West England, North East England and Yorkshire) is deemed to be a separate product for the application of the award criteria. There is no restriction on the number of products that bidders can offer for, or be awarded. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England. The framework may also be used by private sector contractors and agents working on behalf of the above.
II.2.5) Award criteria
Quality criterion: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document
/ Weighting: See over
Cost criterion: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document
/ Weighting: See over
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 4
II.2.1) Title
Yorkshire
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKE
II.2.4) Description of the procurement
Products associated with the lots are listed on Document No 06c of the Invitation to Offer. Each individual National Product Code (NPC) pack description in each of the regions (North of England, North West England, North East England and Yorkshire) is deemed to be a separate product for the application of the award criteria. There is no restriction on the number of products that bidders can offer for, or be awarded. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England. The framework may also be used by private sector contractors and agents working on behalf of the above.
II.2.5) Award criteria
Quality criterion: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document
/ Weighting: See over
Cost criterion: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document
/ Weighting: See over
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
Section V: Award of contract
Contract No: CM/PHR/15/5484
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
08/02/2017
V.2.2) Information about tenders
Number of tenders received: 25
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
For details of the awarded supplier, please see section VI.2
Runcorn
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Total value of the contract/lot:
: 200 311 092.00
GBP
V.2.5) Information about subcontracting
Section VI: Complementary information
VI.3) Additional information
Awarded Suppliers:
AbbVie Ltd,
Accord Healthcare Limited,
Allergan Ltd,
Amgen Ltd,
Aventis Pharma Ltd trading as Sanofi,
Bristol-Myers Squibb Pharmaceuticals Limited,
Chugai Pharma UK Ltd,
Eli Lilly and Company Limited,
Ferring Pharmaceuticals Limited,
Gilead Sciences Ltd,
Ipsen Limited,
Janssen-Cilag Ltd,
Merck Pharmaceuticals,
Merz Pharma UK Ltd,
MSD,
Novo Nordisk Ltd,
Pfizer Ltd,
Pharmacosmos UK Ltd,
Roche Products Ltd,
Sandoz Ltd,
TEVA UK Ltd,
Vifor Pharma,
ViiV Healthcare Ltd.
VI.4) Procedures for review
VI.4.1) Review body
Commercial Medicines Unit
Runcorn
UK
VI.5) Date of dispatch of this notice
21/04/2017